Operating income · 2015–2025
Ascendis Pharma operating income
−$154M+$148M · FY2025
Ascendis Pharma (ASND) reported −$154M in operating income for fiscal 2025, +$148M from the year before.
| Fiscal year | Operating income | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | −$154M | +$148M | Open → |
| FY20242024-12-31 | −$302M | +$191M | Open → |
| FY20232023-12-31 | −$493M | +$99.1M | Open → |
| FY20222022-12-31 | −$592M | −$57.3M | Open → |
| FY20212021-12-31 | −$534M | −$157M | Open → |
| FY20202020-12-31 | −$378M | −$124M | Open → |
| FY20192019-12-31 | −$254M | −$71.0M | Open → |
| FY20182018-12-31 | −$183M | −$56.8M | Open → |
| FY20172017-12-31 | −$126M | −$45.3M | Open → |
| FY20162016-12-31 | −$80.7M | −$34.3M | Open → |
| FY20152015-12-31 | −$46.4M | — | Open → |
Operating income — Operating income is profit from the core business before interest and tax. It strips out financing decisions, so it compares operations rather than balance sheets.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026
Figures are reported under IFRS in EUR and converted to US dollars at ECB reference rates — fiscal 2025 average 0.885 EUR/$ for income items, year-end 0.851 EUR/$ for balance-sheet items.
Operating income at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Ascendis Pharma operating income |url=https://companiesranked.com/en/company/ascendis-pharma/operating-income |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Ascendis Pharma operating income. CompaniesRanked. https://companiesranked.com/en/company/ascendis-pharma/operating-incomeBibTeX
@misc{companiesranked-en-company-ascendis-pharma-operating-income-2026,
author = {{CompaniesRanked}},
title = {{Ascendis Pharma operating income}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/ascendis-pharma/operating-income}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001193125-26-046590 · February 11, 2026
{{cite web |title=Ascendis Pharma operating income — 20-F (0001193125-26-046590) |url=https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-11}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.